Publication

Preclinical evaluation and molecular imaging of HER family dynamics to guide cancer therapy

Kol, K. J-D., 2019, [Groningen]: Rijksuniversiteit Groningen. 175 p.

Research output: ThesisThesis fully internal (DIV)Academic

APA

Kol, K. J-D. (2019). Preclinical evaluation and molecular imaging of HER family dynamics to guide cancer therapy. [Groningen]: Rijksuniversiteit Groningen.

Author

Kol, Klaas Jan-Derk. / Preclinical evaluation and molecular imaging of HER family dynamics to guide cancer therapy. [Groningen] : Rijksuniversiteit Groningen, 2019. 175 p.

Harvard

Kol, KJ-D 2019, 'Preclinical evaluation and molecular imaging of HER family dynamics to guide cancer therapy', Doctor of Philosophy, University of Groningen, [Groningen].

Standard

Preclinical evaluation and molecular imaging of HER family dynamics to guide cancer therapy. / Kol, Klaas Jan-Derk.

[Groningen] : Rijksuniversiteit Groningen, 2019. 175 p.

Research output: ThesisThesis fully internal (DIV)Academic

Vancouver

Kol KJ-D. Preclinical evaluation and molecular imaging of HER family dynamics to guide cancer therapy. [Groningen]: Rijksuniversiteit Groningen, 2019. 175 p.


BibTeX

@phdthesis{6cd0a4ed1c854a8e87c938f146a50d91,
title = "Preclinical evaluation and molecular imaging of HER family dynamics to guide cancer therapy",
abstract = "Insight in changes in membrane expression of human epidermal growth factor receptor (HER) proteins (also known as receptor dynamics) as a result of cancer treatment with HER-targeted agents would be of major interest for clinical decision making. HER-targeted agents affect many processes involved in HER dynamics, but also influence dynamics of other plasma membrane proteins, such as the immune checkpoint PD-L1. Non-invasive molecular imaging could potentially be used as a tool to monitor receptor dynamics. Therefore, the aim was to gain more insight in the effect of HER-targeting agents on HER and PD-L1 dynamics to provide a rationale for future combination therapies. In addition, HER tracers for molecular imaging to evaluate drug tumor targeting, organ distribution and target dynamics were explored.Effects of anti-EGFR monoclonal antibodies imgatuzumab and cetuximab on EGFR dynamics, intracellular signaling and survival were studied in a panel of human EGFR wild-type NSCLC cell lines. We monitored whether changes in EGFR dynamics affect antibody-dependent cellular cytotoxicity responses and tumor cell growth inhibition. Additionally, a PET imaging tracer based on imgatuzumab was employed to study effects of circulating EGFR protein in blood on tumor tracer uptake. A HER3-directed PET tracer was used to visualize HER3 protein dynamics in response to a HER2-targeting therapeutic agent. Finally, we identified EGFR-related signaling pathways regulating PD-L1 membrane expression in EGFR wild-type NSCLC and provided a rationale to explore combinations of immune checkpoint inhibitors with other targeted agents.",
author = "Kol, {Klaas Jan-Derk}",
year = "2019",
language = "English",
isbn = "978-94-034-1339-6",
publisher = "Rijksuniversiteit Groningen",
school = "University of Groningen",

}

RIS

TY - THES

T1 - Preclinical evaluation and molecular imaging of HER family dynamics to guide cancer therapy

AU - Kol, Klaas Jan-Derk

PY - 2019

Y1 - 2019

N2 - Insight in changes in membrane expression of human epidermal growth factor receptor (HER) proteins (also known as receptor dynamics) as a result of cancer treatment with HER-targeted agents would be of major interest for clinical decision making. HER-targeted agents affect many processes involved in HER dynamics, but also influence dynamics of other plasma membrane proteins, such as the immune checkpoint PD-L1. Non-invasive molecular imaging could potentially be used as a tool to monitor receptor dynamics. Therefore, the aim was to gain more insight in the effect of HER-targeting agents on HER and PD-L1 dynamics to provide a rationale for future combination therapies. In addition, HER tracers for molecular imaging to evaluate drug tumor targeting, organ distribution and target dynamics were explored.Effects of anti-EGFR monoclonal antibodies imgatuzumab and cetuximab on EGFR dynamics, intracellular signaling and survival were studied in a panel of human EGFR wild-type NSCLC cell lines. We monitored whether changes in EGFR dynamics affect antibody-dependent cellular cytotoxicity responses and tumor cell growth inhibition. Additionally, a PET imaging tracer based on imgatuzumab was employed to study effects of circulating EGFR protein in blood on tumor tracer uptake. A HER3-directed PET tracer was used to visualize HER3 protein dynamics in response to a HER2-targeting therapeutic agent. Finally, we identified EGFR-related signaling pathways regulating PD-L1 membrane expression in EGFR wild-type NSCLC and provided a rationale to explore combinations of immune checkpoint inhibitors with other targeted agents.

AB - Insight in changes in membrane expression of human epidermal growth factor receptor (HER) proteins (also known as receptor dynamics) as a result of cancer treatment with HER-targeted agents would be of major interest for clinical decision making. HER-targeted agents affect many processes involved in HER dynamics, but also influence dynamics of other plasma membrane proteins, such as the immune checkpoint PD-L1. Non-invasive molecular imaging could potentially be used as a tool to monitor receptor dynamics. Therefore, the aim was to gain more insight in the effect of HER-targeting agents on HER and PD-L1 dynamics to provide a rationale for future combination therapies. In addition, HER tracers for molecular imaging to evaluate drug tumor targeting, organ distribution and target dynamics were explored.Effects of anti-EGFR monoclonal antibodies imgatuzumab and cetuximab on EGFR dynamics, intracellular signaling and survival were studied in a panel of human EGFR wild-type NSCLC cell lines. We monitored whether changes in EGFR dynamics affect antibody-dependent cellular cytotoxicity responses and tumor cell growth inhibition. Additionally, a PET imaging tracer based on imgatuzumab was employed to study effects of circulating EGFR protein in blood on tumor tracer uptake. A HER3-directed PET tracer was used to visualize HER3 protein dynamics in response to a HER2-targeting therapeutic agent. Finally, we identified EGFR-related signaling pathways regulating PD-L1 membrane expression in EGFR wild-type NSCLC and provided a rationale to explore combinations of immune checkpoint inhibitors with other targeted agents.

M3 - Thesis fully internal (DIV)

SN - 978-94-034-1339-6

PB - Rijksuniversiteit Groningen

CY - [Groningen]

ER -

ID: 73871364